DMAC Share Price | DiaMedica Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does DiaMedica Therapeutics, Inc. do?

Overview: DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of recombinant proteins to treat kidney and neurological diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) Market cap: USD 153.09 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.07 Return on Equity: -79.52% Price to Book: 4.51Contact Details: Address: 2 Carlson Pkwy N Ste 260, MINNEAPOLIS MN: 55447-4477 Tel: 1 763 4965454 Fax: 1 763 7104456 Website: https://www.diamedica.com/

Q: Is DiaMedica Therapeutics, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for DiaMedica Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by weekly and monthly MACD indicators both showing bullish signals, along with daily moving averages also indicating bullish momentum. The Bollinger Bands reflect a mildly bullish trend on the weekly chart and a bullish trend on the monthly chart. The On-Balance Volume (OBV) is bullish for both weekly and monthly periods, while the KST shows a bullish weekly signal but is mildly bearish on the monthly. The Dow Theory indicates no trend on the weekly chart and a mildly bullish stance on the monthly chart.In terms of performance, DiaMedica has outperformed the S&P 500 across multiple periods, with a year-to-date return of 24.49% compared to the S&P 500's 12.22%, and a one-year return of 63.68% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

285.74 k

Shareholding (Sep 2025)

FII

0.71%

Held by 23 FIIs

DII

92.55%

Held by 8 DIIs

Promoter

0.00%

How big is DiaMedica Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, DiaMedica Therapeutics, Inc. has a market capitalization of 153.09 million, with net sales of 0.00 million and a net profit of -27.00 million over the latest four quarters. Shareholder's funds are 40.72 million and total assets are 46.34 million as of Dec 24.

View full answer

What does DiaMedica Therapeutics, Inc. do?

22-Jun-2025

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing recombinant proteins for kidney and neurological diseases, with a market cap of approximately $153.09 million. As of March 2025, the company reported a net profit loss of $8 million.

View full answer

Who are in the management team of DiaMedica Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of DiaMedica Therapeutics, Inc. includes Mr. Richard Pilnik (Independent Chairman), Mr. Rick Pauls (President and CEO), Dr. Harry Alcorn, Mr. James Parsons, Dr. Jerry Xiao, and Dr. Michael Giuffre (Independent Director). They oversee the company's strategic direction and operations.

View full answer

Is DiaMedica Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, DiaMedica Therapeutics, Inc. has a bullish technical trend, supported by positive MACD indicators and moving averages, while outperforming the S&P 500 with a year-to-date return of 24.49% compared to 12.22%.

View full answer

Compare DiaMedica Therapeutics, Inc. with Similar Stocks

MediWound Ltd.Milestone Pharmaceuticals, Inc.MediciNova, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 374 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.07

Return on Equity

-61.85%

Price to Book

7.24

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.65%

6 Months

0.0%

1 Year

29.75%

2 Years

137.19%

3 Years

275.56%

4 Years

146.72%

5 Years

-29.8%

DiaMedica Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-200.00%

EBIT to Interest (avg)

-18.68

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.07

Sales to Capital Employed (avg)

Tax Ratio

0.11%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

20.03%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.24

EV to EBIT

-9.48

EV to EBITDA

-9.50

EV to Capital Employed

-88.85

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-61.85%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 11 Schemes (6.74%)

Foreign Institutions

Held by 23 Foreign Institutions (0.71%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -36.51% vs -40.00% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.00",
          "val2": "-6.90",
          "chgp": "-30.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.60",
          "val2": "-6.30",
          "chgp": "-36.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -25.77% vs -41.61% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.60",
          "val2": "-21.20",
          "chgp": "-25.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.40",
          "val2": "-19.40",
          "chgp": "-25.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.00

-6.90

-30.43%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-8.60

-6.30

-36.51%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -36.51% vs -40.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-26.60

-21.20

-25.47%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-24.40

-19.40

-25.77%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -25.77% vs -41.61% in Dec 2023

All Annual Results

Company CV

About DiaMedica Therapeutics, Inc.

DiaMedica Therapeutics, Inc.

Pharmaceuticals & Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of recombinant (synthetic) proteins. The Company uses its technologies for the development and commercialization of recombinant proteins to treat kidney and neurological diseases. The Company’s focus is on chronic kidney disease (CKD) and acute ischemic stroke (AIS). The Company’s lead product DM199, is a drug candidate, a commercial potential as a therapy for CKD and AIS. DM199 is a recombinant form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) produced primarily in the kidneys, pancreas and salivary glands that plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels, which decreases vascular resistance) in the body, as well as an important role in inflammation and oxidative stress.

Company Coordinates

Company Details

2 Carlson Pkwy N Ste 260 , MINNEAPOLIS MN : 55447-4477

Tel: 1 763 4965454

https://www.diamedica.com/

Registrar Details